Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Adenosine Triphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 8/20 | 0.79 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.79 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.76 |
| ▸ | BLM | P54132 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.73 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.73 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.73 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.73 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL29796747 | 1.00 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL29905572 | 0.99 | P2RY1 (0.80) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL29576424 | 0.99 | P2RY1 (0.80) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL193646 | 0.99 | P2RY1 (0.80) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL30606657 | 0.98 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL31149196 | 0.98 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL924732 | 0.98 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL29017896 | 0.98 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL28608115 | 0.98 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL29670849 | 0.98 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113101908-A | Hybrid ligand hierarchical pore metal organic framework material and preparation method and application thereof | 华南理工大学 | 2021-07-13 | — | — | CN | claimed |
| US-20250161212-A1 | LIQUID PHARMACEUTICAL FORMULATION OF OMEPRAZOLE OR ESOMEPRAZOLE | ALKALOID AD SKOPJE (MK) | 2025-05-22 | — | — | US | disclosed |
| WO-2025026441-A1 | USE OF PROTON PUMP REGULATOR IN PREPARATION OF DRUG | 上海魁特迪生物科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| WO-2025002400-A1 | ATP6V1B2 BINDING AGENT AND USE THEREOF | 上海魁特迪生物科技有限公司 | 2025-01-02 | — | — | WO | disclosed |
| EP-4458369-A1 | USE OF PROTON PUMP MODULATOR IN PREPARING REAGENT | Shanghai Quietd Biotechnology Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| US-20240343762-A1 | USE OF PROTON PUMP MODULATOR IN PREPARING REAGENT | SHANGHAI QUIETD BIOTECHNOLOGY CO., LTD. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3474836-B1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | REKIK RAOUF (TN) | 2024-01-17 | — | — | EP | disclosed |
| EP-3965735-B1 | PHARMACEUTICAL FORMULATION COMPRISING A BENZIMIDAZOLE | ALKALOID AD SKOPJE (MK) | 2023-08-30 | — | — | EP | disclosed |
| US-20230172918-A1 | PHARMACEUTICAL FORMULATION | ALKALOID AD SKOPJE (MK) | 2023-06-08 | — | — | US | disclosed |
| US-11634545-B2 | Layered-substance-containing solution and method of manufacturing same | ADEKA CORPORATION (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20040009957-A1 | Protective effects of PDE-5 inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-15 | — | — | US | disclosed |
| WO-2003101276-A2 | PROTECTIVE EFFECTS OF PDE-5 INHIBITORS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2003-12-11 | — | — | WO | disclosed |
| CN-1422272-A | Pyrrolopyridazine compound | SANKYO CO (JP) | 2003-06-04 | — | — | CN | disclosed |
| WO-2001030332-A3 | METHODS OF PROTECTING NEURONAL FUNCTION | UNIV WAKE FOREST (US) | 2002-05-10 | — | — | WO | disclosed |
| US-6313112-B1 | Methods of protecting neuronal function | WAKE FOREST UNIVERSITY | 2001-11-06 | — | — | US | disclosed |
| US-6313112-B1 | Methods of protecting neuronal function | WAKE FOREST UNIVERSITY | 2001-11-06 | — | — | US | disclosed |
| WO-2001030332-A2 | METHODS OF PROTECTING NEURONAL FUNCTION | WAKE FOREST UNIVERSITY (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001030332-A2 | METHODS OF PROTECTING NEURONAL FUNCTION | WAKE FOREST UNIVERSITY (US) | 2001-05-03 | — | — | WO | disclosed |
| CN-1044811-C | Pyrrolopyridazine derivatives | SANKYO CO (JP) | 1999-08-25 | — | — | CN | disclosed |
| CN-1143964-A | Pyrrolopyridazine derivative | SANKYO CO (JP) | 1997-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172918-A1 | PHARMACEUTICAL FORMULATION | PGA5, HRH2, SI | P2RY1 959/4885P2RY11 658/4885ENPP1 1187/4885 |
| US-20250161212-A1 | LIQUID PHARMACEUTICAL FORMULATION OF OMEPRAZOLE OR ESOMEPRAZOLE | PGA5, SI, ATP6AP1 | P2RY1 458/4885P2RY11 272/4885ENPP1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.